Interim results from the KEYNOTE-177 trial have shown significant improvements in patient survival and response in advanced colorectal cancer when treated with pembrolizumab as first-line therapy. The data suggests the treatment should become the new standard of care for the disease.
Recent data presented at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting shows pembrolizumab to be a successful first-line therapy in metastatic, advanced colorectal carcinoma with high microsatellite instability and mismatch repair deficiencies. Significant improvements were observed in progression-free survival, response rate and adverse events.
To view the full article, please register now for access